Research achievements
0000-00-00
Title
Author
Paper
0000-00-00
Title
Author
Paper
0000-00-00
Title
Author
Paper
CN
ZL 202080059073.1
2024년 8월 6일
재조합 보툴리눔 독소
KR
10-2610179
2023년 11월 30일
재조합 보툴리눔 독소
KR
10-2547393
2023년 6월 20일
재조합 보툴리눔 독소
KR
10-2597062
2023년 10월 27일
재조합 보툴리눔 독소
KR
10-2731131
2024년 3월 7일
재조합 보툴리눔 독소
KR
출원
2024년 10월 24일
재조합 보툴리눔 독소
KR
출원
2024년 3월 7일
재조합 보툴리눔 독소
US
출원
2023년 10월 17일
재조합 보툴리눔 독소
EU
출원
2022년 2월 22일
재조합 보툴리눔 독소
US
출원
2022년 2월 22일
재조합 보툴리눔 독소
IN
출원
2022년 2월 21일
재조합 보툴리눔 독소
Recombinant BoNT
Through MVRIX's approach to next-generation botulinum toxins, we have developed recombinant botulinum toxin. From early production stages to diverse applications, we are exploring new possibilities with this differentiated botulinum toxin.
Challenging the Limits of Botulinum Toxin :
Recombinant BoNT
Solving Strain Issues and Resistance Problems
Pure Toxin Gene for Production in E. coli
MVRIX uses E. coli as the host for botulinum toxin production, eliminating the risk of disputes related to the wild-type Clostridium botulinum strain.
Core Toxin Production to Minimize Resistance
By producing only the pure toxin gene from the initial stages, MVRIX avoids additional purification steps and significantly reduces the risk of resistance.
Expanding Potential Applications
Diverse Botulinum Toxin Types
MVRIX holds multiple serotypes of botulinum toxin and analyzes the unique characteristics of each type and region of action.
New Chimeric Botulinum Toxin Engineering
By engineering different combinations of toxin regions, we expand the versatility, duration, and range of indications for botulinum toxin, pushing the boundaries of its potential applications.
Safe and Fast Production
MVRIX's Two-Part Production Method
MVRIX produces botulinum toxin using E. coli as a host, instead of Clostridium botulinum. Rather than producing the entire core toxin at once, we employ a two-part production method, where the toxin is divided into two non-toxic fragments. These fragments are assembled in the final stage of processing, activating the toxin.
Minimizing Risks, Maximizing Efficiency
Since the toxin remains inactive until the assembly stage, production can be safely conducted at a BSL-2 level.
The entire process, from cultivation to final assembly, takes only one week—one-third of the time required by conventional methods, significantly improving time efficiency.
Core Toxin with Reduced Resistance Risk
Core toxins do not induce resistance to botulinum toxin. With MVRIX’s innovative production method, core toxins can be produced faster and more safely.
Botulinum Toxin with Fast Onset and Long-Lasting Effect
Through protein engineering, MVRIX develops botulinum toxins that act faster and last longer.
Expanding Applications
By engineering each of the three domains of botulinum toxin, MVRIX develops customized toxins for diverse indications.
MVRIX’s recombinant botulinum toxin technology leads the next-generation market with diverse, customized core toxins
What is Botulinum Neurotoxin?
Botulinum toxin is a protein toxin produced by the anaerobic bacterium Clostridium Botulinum. It is known as the most potent toxin, with an LD50 (the dose lethal to 50% of test subjects) in mice of 0.0003–0.00003 μg/kg, making it over 30,000 times more potent than the commonly known pufferfish toxin (LD50: 10 μg/kg). Due to its extreme potency, strict safety measures are essential to prevent any release of the strain or toxin into the environment during production and handling.
Botulinum toxin consists of three main structural domains.
Botulinum toxin paralyzes muscles by inhibiting the release of neurotransmitters from nerve cells.
Botulinum toxin has seven serotypes (A through G), with types A, B, E, and F being toxic to humans. Each serotype includes around 40 subtypes, and A1 has been the most widely used since its introduction in 1987. Research into various subtypes is ongoing to address resistance issues and meet the therapeutic market demands.
MVRIX leverages an understanding of the unique characteristics of each serotype and subtype to develop customized botulinum toxins through chimeric manufacturing.
Botulinum toxin produced by Clostridium botulinum is a 900kDa protein complex, with only the 150kDa core toxin responsible for its toxic effects. The remaining 750kDa non-toxic proteins can be recognized as antigens by immune cells, potentially causing resistance. Currently, only three companies globally offer core toxin products with reduced resistance risk.
MVRIX has developed recombinant technology to produce core toxin through a streamlined process, removing the need for additional purification steps.
